Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290830517> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4290830517 endingPage "e2.174" @default.
- W4290830517 startingPage "e2.174" @default.
- W4290830517 abstract "Background Aquaporin-4 (AQP4) antibody associated neuromyelitis optica spectrum disorder (NMOSD) requires long-term immunomodulation. In refractory cases rituximab can be used, however the optimal regime is not established. Methods We retrospectively examined different rituximab regimes in AQP4-NMOSD. Standard mono- therapy (SM; 6 monthly infusions), SM plus oral steroids (SM+S), extended interval dosing (EID; with retreat- ment at CD19 >1%) and EID with oral steroids (EID+S) were compared. The primary outcome was time to first clinical relapse. Potential confounders including age, gender, number of previous relapses, and onset phenotype were included. Results 77 patients were included: 67 females, mean age 34.6, median DSS at rituximab initiation 5.0. 40 were on SM+S, 19 on SM, 8 on EID, and 10 on EID+S, with mean follow-up 38.5 months. 25/77 patients relapsed on rituximab. Median time to first relapse was 39 months (SM+S), 46 months (SM), 54 months (EID) and 42 months (EID+S). Adjusted Cox proportional hazard model revealed no significant difference between rituximab regimes (SM+S as reference; hazard ratio for SM 1.39, 95%CI 0.49–4.1, p=0.55; hazard ratio for EID 0.70, 95%CI 0.15–3.3, p=0.65; hazard ratio for EID+S 1.63, 95%CI 0.48–5.5, p=0.43). 9 significant infections were recorded, 3 in the SM group and 6 in SM+S. Conclusions This provides initial evidence that EID could be used for long term treatment of NMOSD. This may improve patient experience and consolidate use of hospital resources." @default.
- W4290830517 created "2022-08-12" @default.
- W4290830517 creator A5003512718 @default.
- W4290830517 creator A5016778416 @default.
- W4290830517 creator A5019299318 @default.
- W4290830517 creator A5036881488 @default.
- W4290830517 creator A5040104467 @default.
- W4290830517 creator A5056651699 @default.
- W4290830517 creator A5070021548 @default.
- W4290830517 creator A5080342290 @default.
- W4290830517 creator A5085014737 @default.
- W4290830517 creator A5090057155 @default.
- W4290830517 date "2022-08-12" @default.
- W4290830517 modified "2023-10-18" @default.
- W4290830517 title "Impact of rituximab regime on time to relapse in aquaporin-4 antibody positive neuromyelitis spectrum disorder" @default.
- W4290830517 doi "https://doi.org/10.1136/jnnp-2022-abn2.29" @default.
- W4290830517 hasPublicationYear "2022" @default.
- W4290830517 type Work @default.
- W4290830517 citedByCount "0" @default.
- W4290830517 crossrefType "journal-article" @default.
- W4290830517 hasAuthorship W4290830517A5003512718 @default.
- W4290830517 hasAuthorship W4290830517A5016778416 @default.
- W4290830517 hasAuthorship W4290830517A5019299318 @default.
- W4290830517 hasAuthorship W4290830517A5036881488 @default.
- W4290830517 hasAuthorship W4290830517A5040104467 @default.
- W4290830517 hasAuthorship W4290830517A5056651699 @default.
- W4290830517 hasAuthorship W4290830517A5070021548 @default.
- W4290830517 hasAuthorship W4290830517A5080342290 @default.
- W4290830517 hasAuthorship W4290830517A5085014737 @default.
- W4290830517 hasAuthorship W4290830517A5090057155 @default.
- W4290830517 hasConcept C118552586 @default.
- W4290830517 hasConcept C121332964 @default.
- W4290830517 hasConcept C126322002 @default.
- W4290830517 hasConcept C142424586 @default.
- W4290830517 hasConcept C187212893 @default.
- W4290830517 hasConcept C203014093 @default.
- W4290830517 hasConcept C207103383 @default.
- W4290830517 hasConcept C2777154362 @default.
- W4290830517 hasConcept C2779338263 @default.
- W4290830517 hasConcept C2780640218 @default.
- W4290830517 hasConcept C2780653079 @default.
- W4290830517 hasConcept C2781137167 @default.
- W4290830517 hasConcept C44249647 @default.
- W4290830517 hasConcept C50382708 @default.
- W4290830517 hasConcept C71924100 @default.
- W4290830517 hasConcept C87355193 @default.
- W4290830517 hasConcept C90924648 @default.
- W4290830517 hasConceptScore W4290830517C118552586 @default.
- W4290830517 hasConceptScore W4290830517C121332964 @default.
- W4290830517 hasConceptScore W4290830517C126322002 @default.
- W4290830517 hasConceptScore W4290830517C142424586 @default.
- W4290830517 hasConceptScore W4290830517C187212893 @default.
- W4290830517 hasConceptScore W4290830517C203014093 @default.
- W4290830517 hasConceptScore W4290830517C207103383 @default.
- W4290830517 hasConceptScore W4290830517C2777154362 @default.
- W4290830517 hasConceptScore W4290830517C2779338263 @default.
- W4290830517 hasConceptScore W4290830517C2780640218 @default.
- W4290830517 hasConceptScore W4290830517C2780653079 @default.
- W4290830517 hasConceptScore W4290830517C2781137167 @default.
- W4290830517 hasConceptScore W4290830517C44249647 @default.
- W4290830517 hasConceptScore W4290830517C50382708 @default.
- W4290830517 hasConceptScore W4290830517C71924100 @default.
- W4290830517 hasConceptScore W4290830517C87355193 @default.
- W4290830517 hasConceptScore W4290830517C90924648 @default.
- W4290830517 hasIssue "9" @default.
- W4290830517 hasLocation W42908305171 @default.
- W4290830517 hasOpenAccess W4290830517 @default.
- W4290830517 hasPrimaryLocation W42908305171 @default.
- W4290830517 hasRelatedWork W2792073375 @default.
- W4290830517 hasRelatedWork W2904525722 @default.
- W4290830517 hasRelatedWork W3007180278 @default.
- W4290830517 hasRelatedWork W3034094644 @default.
- W4290830517 hasRelatedWork W3142600709 @default.
- W4290830517 hasRelatedWork W3163251843 @default.
- W4290830517 hasRelatedWork W3164368870 @default.
- W4290830517 hasRelatedWork W4287834177 @default.
- W4290830517 hasRelatedWork W4290830517 @default.
- W4290830517 hasRelatedWork W4293572012 @default.
- W4290830517 hasVolume "93" @default.
- W4290830517 isParatext "false" @default.
- W4290830517 isRetracted "false" @default.
- W4290830517 workType "article" @default.